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Abstract
Background: Previous studies have used social network variables to improve our understanding
of HIV transmission. Similar analytic approaches have not been undertaken for hepatitis C (HCV)
or B (HBV), nor used to conduct comparative studies on these pathogens within a single setting.
Methods: A cross-sectional survey consisting of a questionnaire and blood sample was conducted
on injection drug users in Winnipeg between December 2003 and September 2004. Logistic
regression analyses were used to correlate respondent and personal network data with HCV, HBV
and HIV prevalence.
Results: At the multivariate level, pathogen prevalence was correlated with both respondent and
IDU risk network variables. Pathogen transmission was associated with several distinct types of
high-risk networks formed around specific venues (shooting galleries, hotels) or within users who
are linked by their drug use preferences. Smaller, isolated pockets of IDUs also appear to exist
within the larger population where behavioural patterns pose a lesser risk, unless or until, a given
pathogen enters those networks.
Conclusion: The findings suggest that consideration of both respondent and personal network
variables can assist in understanding the transmission patterns of HCV, HBV, and HIV. It is
important to assess these effects for multiple pathogens within one setting as the associations
identified and the direction of those associations can differ between pathogens.
Background
The likelihood of exposure to bloodborne pathogens is a
multifactoral process primarily dependent on the risk
behaviours an individual practices and the likelihood that
a susceptible individual will come into contact with an
infected individual (thus increasing or decreasing the risk
actually associated with a risk behaviour). The interac-
tions that bring susceptible and infected individuals into
contact with each other occur within the context of social
networks, the overall structure of which can also affect the
rate of pathogen spread [1,2]. Chance events also play a
role as a social network may contain a group of individu-
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als whose behaviours favour transmission, but until such
time as a bloodborne pathogen enters that network, they
face no risk of acquiring that pathogen.
Individual risk behaviours for injection drug users (IDU)
include those directly associated with transmission, such
as the use of syringes previously used by another IDU or
those behaviours which can act as markers of the above
types of behaviours. Examples of risk markers that are pos-
itively associated with disease prevalence include drug
scene roles, such as dealing drugs or injecting others as a
service (street or hit doctors) [3-6]. Other behaviours,
such as obtaining clean needles from questionable
sources such as drug dealers, shooting gallery owners, or
on the street, can also act as a marker of an increased prob-
ability of using a contaminated needle, as doctoring of
used needles to make them appear new has been reported
[7].
Social network analysis is a technique which measures
and analyzes the interactions that occur between people
and its application can enhance an otherwise overly sim-
plistic interpretation of individual risk behaviours. In
Brooklyn, injecting with a used syringe was associated
with HIV only if syringes were being shared with someone
who was 10 or more years older than the interviewed sub-
ject, or was a daily injector [8]. By incorporating network
variables indicative of a higher probability of coming into
contact with an infected individual, a better indication is
obtained of who is at risk of infection and what actually
constitutes a high-risk behaviour.
Subsequent research on IDU and their network character-
istics have identified other network variables associated
with transmission risk. High-risk injection practices have
been linked to network characteristics such as the number
of network members [9,10]; the presence of family mem-
bers or spouses within the network [4,11]; higher network
density [10]; the setting where injection takes place [10];
turnover of network members [12]; and the pooling of
financial resources within networks for the purpose of
obtaining drugs [9]. Racial/ethnic differences in HIV prev-
alence have also been at least partially explained by taking
into account the differing network characteristics of differ-
ent ethnic groups [13].
Some individual behaviours or characteristics may also be
proxy markers of network behaviours. The type of drug an
IDU chooses to inject can be measured as a characteristic
of the individual injector and itself can influence risk, as
some drugs, like cocaine, are prepared at room tempera-
ture and hence are more conducive to pathogen survival
[14]. In addition to these more risky drug-specific prac-
tices, IDU may form networks based on drug type, which
mark the broader social network within which an individ-
ual is a member [15,16]. Therefore, network members are
more likely to come into contact with whichever patho-
gen(s) happen to be circulating within that network. Sim-
ilarly, moving to a new city within the past year can also
be an indicator of higher risk as individuals create a social
bond through the sharing of drug equipment to try and
establish themselves in new networks [12,17].
We have recently described networks centered on down-
town hotels in the core area of Winnipeg (manuscript in
press), which demonstrate that the setting where an indi-
vidual injects drugs can also act as a proxy marker of a
social network in which some of the members may not
know each other, but are nonetheless linked by a com-
mon venue. Within these venues accidental or intentional
use of contaminated syringes is more likely. Injection at a
shooting gallery is another example of a geographic place-
based network that has also frequently been linked to
increased risk of infection by a bloodborne pathogen
[6,18,19].
The majority of the network research described above has
focused on HIV and relatively little on hepatitis B and C
(HBV and HCV, respectively). Comparative studies of net-
work variables associated with the transmission of HIV,
HCV and HBV within the same setting have also not been
conducted. Our goal was to determine whether respond-
ent and network variables (including some proxy markers
of networks as described above) are associated with the
prevalence of HCV, HBV, and HIV in our setting and to
what extent similar or dissimilar patterns emerge for the
different pathogens.
Methods
Study setting
A cross-sectional survey of IDU in Winnipeg, Manitoba,
Canada (pop. 675,000) from December, 2003 to Septem-
ber, 2004 was conducted. Potential study recruits were
invited to participate through advertisements posted at
local community health centres, and meeting places such
as laundromats, which had been suggested by key inform-
ants within the target population. Word-of-mouth adver-
tising also occurred in the community as the study
progressed.
Eligibility criteria were self-reported use of illicit injection
drugs in the 6 month period prior to interview and age 15
years or more. Potential participants made telephone con-
tact with the study nurse, who administered all the surveys
and collected a blood specimen. An honorarium of $40
Cdn was provided to all study participants, regardless of
whether they completed all parts of the study. Participants
provided written or oral consent. The study design was
approved by the Health Research Ethics Board of the Uni-BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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versity of Manitoba and the Winnipeg Regional Health
Authority Research Review Committee.
Survey instrument
The questionnaire was divided into three sections. Section
1 consisted of questions based on the respondent's own
demographic or behavioural characteristics (hereafter
referred to as respondent variables).
Section 2 elicited information on the study participant's
egocentric network. Study participants were asked to
think back over the last 30 days about the people with
whom they had had more than casual contact. Prompts
included friends, relatives, or other individuals to whom
they feel close, and people with whom they had used
drugs, had sex, resided, or hung out. Using initials or
other anonymous identifiers, participants were asked to
list a maximum of 20 members of their egocentric net-
work (referred to as egocentric variables).
Section 3 elicited information on the respondent's IDU
risk network. In this section, a series of detailed questions
were asked about each of the individuals within the ego-
centric network that had been identified by the respond-
ent as IDU (to a maximum of 5 IDU). If more than 5 IDU
were listed in the egocentric network, only the first 5 IDU
that were listed in the egocentric network were chosen.
Respondents then were asked questions about each mem-
ber of his or her IDU network (e.g. have you ever used a
syringe after [person] used it first?). Respondents could
then provide different responses for each of the IDU
within their risk network (these variables are referred to
IDU risk network variables).
Measures
Respondent sociodemographic variables
Demographic variables included age, age of initiation of
injection drug use (analyzed as number of years a
respondent had injected drugs; referred to as "years of ID
use"), gender, level of education completed, ethnicity and
whether respondents had moved to Winnipeg in the past
year.
Preliminary examination of the data indicated age and
years of ID use were correlated; years of ID use only was
chosen for use in this analysis. The relationship between
years of ID use and serostatus was nonlinear (examined
with Lowess smoothed plots [20]). In general, during the
first years of drug use, there was a rapid increase in serosta-
tus, followed by a more gradual increase until approxi-
mately year 20 after which it leveled off (data not shown).
These breakpoints approximated the quartile distribution
of years of ID use, therefore this variable was recoded to
quartiles.
Due to small sample size, transgender persons (n = 5) and
those reporting an ethnicity other than Caucasian or Abo-
riginal (n = 10) were excluded from analysis. Educational
level was coded to two categories: individuals who
dropped out of school and those who graduated grade 12
or were currently in school. A recent move to Winnipeg
was categorized as those respondents who had moved to
Winnipeg in the past year.
Respondent drug-related behaviours
Respondents were asked questions about their drug-
related behaviours, which generally covered the 6 month
period prior to interview, but exceptions are noted. Three
variables represented use of the three most common
drugs: cocaine, a combination of talwin and ritalin (tal-
win/ritalin) and morphine. A fourth variable for heroin
injection (a relatively rare drug in Winnipeg) was
included for means of comparison with other studies and
because anecdotal evidence suggested that heroin users
may be somewhat isolated from other types of users in
Winnipeg forming a distinct network with distinct proper-
ties. Frequency of drug use was coded as daily vs. non-
daily use.
Two binary variables contained data on injection at hotels
or shooting galleries. Data on whether respondents had
used anyone else's used syringes (ever and during the last
6 months); other related drug-preparation equipment
(last 6 months; prompts included cooker, rinse water, or
cotton); engaged in drug transfer behaviours (prompts
included backloading, frontloading or piggybacking)
from another user's syringe to their own (last 6 months)
were evaluated. Univariate analysis showed that only ever-
use of previously used syringes was significant and is the
only one of the above variables presented in this paper
(e.g. the univariate OR relating HBV serostatus and use of
other's equipment was 0.98 [0.62, 1.55] while the univar-
iate OR for HBV serostatus and engaging in drug transfer
behaviours was 0.94 [0.53, 1.67]). Injecting someone as a
service was defined as someone who reported that he or
she had ever received any money, drugs, or other goods in
exchange for injecting someone with drugs.
Obtaining needles from questionable sources such drug
dealers, shooting gallery owners, or syringes found on the
street was evaluated separately from those who obtained
needles from friends or family members, both in the last
six months. Both were constructed as binary variables.
While sexual behaviours are linked to HBV and HIV trans-
mission, they are not considered an important route of
transmission for HCV, but still indicate certain roles or
networks which may be relevant and predictive of risk. We
included six binary variables denoting opposite-sex or
same-sex sex partnerships in the last six months of the fol-BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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lowing type; regular (someone with whom the participant
is emotionally involved with), casual (someone with
whom the participant has had sex with only a few times
and has no emotional involvement with) or client (some-
one who has given the participant money or goods in
exchange for sex).
Egocentric network variables
We created two continuous variables from the total
number of people on the network list whom the partici-
pant identified as IDU and the total number of people on
the list who were identified as both IDU and family mem-
bers.
IDU risk network variables
A series of variables were based on the interactions which
participants had with individual IDU within their egocen-
tric network (maximum five IDU as noted above). For
example. a participant could indicate that he or she saw
daily anywhere from none to five of the IDU on their IDU
risk network list. To avoid small cell sizes, data were col-
lapsed to either three (0, 1, or 2–5 IDU) or four (0, 1, 2,
or 3–5 IDU) dummy variable categories. Twelve interac-
tions with other IDU were considered, including how
many IDU risk members 1) the participant sees on a daily
basis, 2) inject daily, 3) have been IDU for more than 5
years, 4) have injected at a hotel, 5), have injected at a
shooting gallery, 6) the participant has pooled resources
with to obtain drugs, 7) have used a syringe before the
participant has used it, 8) have used other drug prepara-
tion equipment before the participant has used it, 9) have
initiated the respondent to drug use, 10) have shown the
respondent how to inject drugs, 11) have injected the
respondent with drugs, 12) use talwin/ritalin, 13)
cocaine, or 14) morphine (heroin was not included here
as only 18 respondents knew any heroin users). Variables
7 and 8 are similar to respondent variables regarding the
sharing of syringes and equipment (across all partners),
however, we felt asking the questions within a network
context may result in better recall of these events. Simi-
larly, given the importance of drug type and infection risk,
we included variables 12–14.
Diagnostic testing
Venous blood specimens were collected for HCV, HBV
and HIV serological testing at Cadham Provincial Labora-
tory (Winnipeg, MB). Specimens were screened for HCV
and HIV with AxSYM HCV (Abbott, Mississauga, ON) and
AxSYM HIV1/2 gO (Abbott, Mississagua, ON), respec-
tively. Presumptive positives were confirmed for HCV
with Chiron HCV 3.0 RIBA (Ortho-Clinical Diagnostics,
Markham, ON). Presumptive HIV positive specimens
were confirmed by western blot (BioRad, Montreal, QC).
HBV cases were considered to be those specimens positive
for antibodies against HBV core protein (IMX HBV core
IgG, Abbott, Mississauga, ON).
Statistical analysis
Logistic regression was used to analyze the three binary
dependent variables (HCV, HBV, and HIV serostatus). The
multicollinearity of independent variables was first
assessed with a correlation matrix [21]. As noted above,
age and years of ID use were correlated and years of ID use
was chosen for analysis. The only other two variables that
were clearly correlated were respondent's use of talwin/
ritalin and use of talwin/ritalin by IDU risk network mem-
bers. Given that we were interested in comparing variables
from an individual vs. network perspective, we did not
want to choose one of these variables over the other, nor
combine them into one variable. Therefore, for each path-
ogen, we constructed two models where either one or the
other of the above variables was used. In all cases, the
inclusion of one of these variables over the other had no
major effect on the other independent variables that
remained in the final models or on the final odds ratios
(data not shown). We present only the models using IDU
risk network use of talwin/ritalin as it illustrated a trend
toward increasing prevalence for some pathogens as the
number of talwin/ritalin users within the risk network
increased. All remaining variables that were entered into
multivariable analysis were also checked for multicolline-
arity using NCSS (Kaysville, UT). Variance inflation factor
and tolerance statistics were within acceptable limits for
all variables.
Univariate analyses were first completed and all variables
with p values of 0.2 or less were considered for inclusion
in multivariable analyses. Logistic regression model
building procedures followed those described by Hosmer
and Lemeshow [20]. Multivariable analysis was first con-
ducted by entering respondent variables into a regression
model. The effect of removing individual variables was
assessed through the likelihood ratio test. After final selec-
tion of respondent variables, egocentric and IDU risk net-
work variables were entered and the effect of removing
each respondent and network variable was again tested
with the likelihood ratio test. After creating preliminary
main effects models, interactions were assessed between
the respondent variable, injection with a used syringe, and
all other variables in the model. These interactions were
assessed to determine whether any of the variables in the
model may affect the risk associated with syringe sharing.
All statistical analysis was done using STATA version 8
(Stata corporation, College Station, TX). Diagnostics for
the final models were performed using the Hosmer-Leme-
show goodness of fit statistic and the area under the
receiver operating characteristic curve using the lfit and
lroc commands in STATA [20].BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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Results
A total of 435 IDU were enrolled in the study. Some IDU
were unable or unwilling to provide a blood specimen.
Additionally, five individuals who self-identified as trans-
gender and 10 individuals who self-identified as belong-
ing to ethnic groups other than Caucasian or Aboriginal,
were excluded from the analysis. For the remaining 369
respondents, summary statistics for the egocentric net-
work are as follows: mean number of members, 8.8;
median, 8; range, 1–20, lower quartile, 5; upper quartile,
11; SD, 4.6. Given that the IDU risk network was trun-
cated at 5 IDU, we also report these summary statistics for
the total number of people within the egocentric network
identified as IDU: mean number of IDU in the egocentric
network, 3.5; median, 3; range, 0–20; lower quartile, 1;
upper quartile, 5. In total, 17% of respondents (66/369)
reported more than 5 IDU in their egocentric network.
The lack of data on these individuals is discussed further
in the limitations section of this paper. Of the 369
respondents considered for analysis, several indetermi-
nate results were identified for each pathogen therefore,
the final sample sizes for HCV, HBV, and HIV were 365,
364, and 360, respectively.
Correlation between HCV, HBV, and HIV
To assist in data interpretation the correlation between
HCV, HBV, and HIV were determined. Pairwise correla-
tion values for HCV/HBV serostatus was 0.001; HCV/HIV,
-0.011; and HBV/HIV, -0.011. No apparent correlation
between the three pathogens was evident.
Univariate analyses
The univariate analyses for these 3 pathogens are shown
in tables 1, 2, 3. In univariate analyses, the subset of vari-
ables associated with serostatus and the direction of that
association was similar for the three pathogens. Respond-
ent variables positively associated with serostatus for all
three pathogens were: years of ID use, aboriginal ethnic-
ity, injection at a shooting gallery, ever reporting the use
of someone's else's used syringe; injecting someone else as
a service; and having opposite-sex client partners.
Thirteen variables were associated with both HCV and
HBV, but not HIV. Positive associations were found for
two respondent variables (having injected at a hotel;
injecting talwin/ritalin), two egocentric network variables
(total number of IDU; total number of family IDU), and
five IDU risk network variables (the number of IDU who
inject daily, the number of IDU who have been injecting
for more than 5 years, the number of IDU who have
injected talwin/ritalin, the number of IDU who have
injected at a hotel, and the number of IDU who have used
a syringe before the respondent used it). Negative associ-
ations were found for three respondent variables (moved
to Winnipeg in the previous year; injection of heroin and
daily injection) and one IDU risk network variable
(number of IDU who initiated the respondent to injection
drug use).
Two respondent variables were associated with HCV and
HIV, but not HBV. A negative association was found for
obtaining clean syringes from friends. Reporting same-sex
regular sex partners was negatively associated with HCV
and positively associated with HIV.
Ten variables were associated with only one of the three
pathogens. Positive associations were found between
HCV and one respondent variable (obtains clean syringes
from questionable sources); between HBV and four IDU
risk network variables (the number of IDU in the risk net-
work who have injected at a shooting gallery; the number
of IDU with whom the respondent has pooled resources;
the number of IDU who have injected the respondent and
the number of IDU who have injected cocaine); between
HIV and two respondent variables (injection of cocaine
and same-sex client sex partners). Negative associations
were found between HBV and reporting same-sex casual
sex partners and opposite-sex casual partners and between
HCV and the number of IDU in the risk network who
have shown the respondent how to inject drugs.
Multivariate analyses
In multivariate analysis, prior to assessing interactions,
HCV was positively associated with respondent's age of
initiation to injection drug use, reported injection with a
syringe used by another IDU, injection at a shooting gal-
lery, injecting someone as a service, and the number of
IDU in the risk network who inject talwin/ritalin (table 4).
Negative associations for this pathogen were found for the
respondent obtaining syringes from friends and the
number of IDU in the risk network who had shown the
respondent how to inject drugs.
For the model described above, interactions were assessed
between the respondent variable, injection with a used
syringe, and the remaining variables in the model. An
interaction was noted between injection with used
syringes and the number of IDU network members who
inject talwin/ritalin and the number of IDU network
members who had shown the respondent how to inject
drugs (table 5). For respondents who did not associate
with other talwin/ritalin users, injecting with syringes pre-
viously used by other IDUs was positively associated with
HCV prevalence. This correlation was absent among those
IDU linked to talwin and ritalin, such that their HCV prev-
alence was high regardless of whether or not they reported
injecting with used syringes. Similarly, for those IDU who
were in a risk network where someone had shown them
how to inject drugs, HCV prevalence was relatively low
and not associated with injection with a used syringe.BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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Table 1: Odds ratios and 95% confidence intervals for univariate analysis of HCV serostatus.
Variable name HCV negative (n = 167) (%) HCV positive (n = 198) (%) OR (95% CI) p value
Respondent variables
Years of injection drug use (quartiles)
0–6 81 (48.5) 20 (10.1) 1.0
7–13 46 (27.5) 51 (25.8) 4.5 (2.4–8.4) <0.001
14–21 19 (11.4) 61 (30.8) 13.0 (6.4–26.5) <0.001
22–39 21 (12.6) 66 (33.3) 12.7 (6.4–25.5) <0.001
Gender
Male 96 (57.5) 113 (57.1) 1.0
Female 71 (42.5) 85 (42.9) 1.0 (0.7–1.5) 0.937
Education level
< grade 12 116 (69.5) 142 (71.7) 1.0
> grade 12 51 (30.5) 56 (28.3) 0.9 (0.6–1.4) 0.637
Ethnicity
Caucasian 71 (42.5) 57 (28.8) 1.0
Aboriginal 96 (57.5) 141 (71.2) 1.8 (1.2–2.8) 0.006
Moved to Winnipeg in past year
No 112 (67.1) 153 (77.3) 1.0
Yes 55 (32.9) 45 (22.7) 0.6 (0.4–1.0) 0.030
Deals drugs
No 85 (50.9) 107 (54.0) 1.0
Yes 82 (49.1) 91 (46.0) 0.9 (0.6–1.3) 0.549
Cocaine use
No 62 (37.1) 69 (34.9) 1.0
Yes 105 (62.9) 129 (65.1) 1.1 (0.7–1.7) 0.651
Talwin/ritalin use
No 134 (80.2) 113 (57.1) 1.0
Yes 33 (19.8) 85 (42.9) 3.1 (1.9–4.9) <0.001
Morphine use
No 110 (65.9) 121 (61.1) 1.0
Yes 57 (34.1) 77 (38.9) 1.2 (0.8–1.9) 0.347
Heroin use
No 145 (86.8) 184 (92.9) 1.0
Yes 22 (13.2) 14 (7.1) 0.5 (0.2–1.0) 0.052
Injects daily
No 20 (12.0) 43 (21.7) 1.0
Yes 147 (88.0) 155 (78.3) 0.5 (0.3–0.9) 0.013
Injected at a hotel
No 109 (65.3) 107 (54.0) 1.0
Yes 58 (34.7) 91 (46.0) 1.6 (1.0–2.4) 0.029
Injected at a shooting gallery
No 153 (91.6) 156 (78.8) 1.0
Yes 14 (8.4) 42 (21.2) 2.9 (1.5–5.6) <0.001
Ever used someone else's syringe
No 90 (53.9) 49 (24.8) 1.0
Yes 77 (46.1) 149 (75.3) 3.6 (2.3–5.5) <0.001
Injected someone else as a serviceBMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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No 144 (86.2) 125 (63.1) 1.0
Yes 23 (13.8) 73 (36.9) 3.7 (2.2–6.2) <0.001
Obtains syringes from friends
No 50 (29.9) 73 (36.9) 1.0
Yes 117 (70.1) 125 (63.1) 0.7 (0.5–1.1) 0.162
Obtains syringes from questionable sources
No 135 (80.8) 144 (72.7) 1.0
Yes 32 (19.2) 54 (27.3) 1.6 (1.0–2.6) 0.067
Opposite-sex regular partners
No 51 (30.5) 65 (31.8) 1.0
Yes 116 (69.5) 163 (68.2) 0.9 (0.6–1.4) 0.640
Opposite-sex casual partners
No 101 (60.5) 129 (65.2) 1.0
Yes 66 (39.5) 69 (34.9) 0.8 (0.5–1.3) 0.357
Opposite-sex client partners
No 151 (90.4) 163 (82.3) 1.0
Yes 16 (9.6) 35 (17.7) 2.0 (1.1–3.8) 0.024
Regular same-sex partners
No 160 (95.8) 195 (98.5) 1.0
Yes 7 (4.2) 3 (1.5) 0.4 (0.1–1.4) 0.116
Casual same-sex partners
No 160 (95.8) 191 (96.5) 1.0
Yes 7 (4.2) 7 (3.5) 0.8 (0.3–2.4) 0.745
Client same-sex partners
No 163 (97.6) 194 (98.0) 1.0
Yes 4 (2.4) 4 (2.0) 0.8 (0.2–3.4) 0.808
Egocentric network variables (maximum number of network members = 20)
Total number of IDU in network
Median (IQR) 3 (1,5) 3 (1,5) 1.0 (1.0–1.1) 0.194
Total number of IDU family members in network
Median (IQR) 0 (0,0) 0 (0,1) 1.29 (1.1–1.6) 0.10
Spouse IDU in network
No 109 (65.3) 127 (64.1) 1.0
Yes 58 (34.7) 71 (35.9) 1.1 (0.7–1.6) 0.822
IDU risk network variables (maximum number of IDU = 5)
Number of IDU respondent sees daily
None 54 (32.3) 66 (33.3) 1.0
1 55 (32.9) 68 (34.3) 1.0 (0.6–1.7) 0.964
2 32 (19.2) 30 (15.2) 0.8 (0.4–1.4) 0.398
3–5 26 (15.6) 34 (17.2) 1.1 (0.6–2.0) 0.832
Number of IDU in network who inject daily
None 104 (62.3) 105 (53.0) 1.0
1 32 (19.2) 36 (18.2) 1.1 (0.6–1.9) 0.699
2 19 (11.4) 31 (15.7) 1.6 (0.9–3.0) 0.137
3–5 12 (7.2) 26 (13.1) 2.1 (1.0–4.5) 0.042
Number of IDU in network who have been IDU for >5 years
0 101 (60.5) 74 (37.4) 1.0
1 28 (16.8) 40 (20.2) 1.9 (1.1–3.4) 0.021
Table 1: Odds ratios and 95% confidence intervals for univariate analysis of HCV serostatus. (Continued)BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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2 18 (10.8) 39 (19.7) 3.0 (1.6–5.6) 0.001
3–5 20 (12.0) 45 (22.7) 3.1 (1.7–5.6) <0.001
Number of IDU in network who have injected at a hotel
0 117 (70.1) 112 (56.6) 1.0
1 29 (17.4) 39 (19.7) 1.4 (0.8–2.4) 0.222
2–5 21 (12.6) 47 (23.7) 2.3 (1.3–4.2) 0.004
Number of IDU in network who have injected at a shooting gallery
0 134 (80.2) 143 (72.2) 1.0
1 18 (10.8) 27 (13.6) 1.4 (0.7–2.7) 0.298
2–5 15 (9.0) 28 (14.1) 1.7 (0.9–3.4) 0.102
Number of IDU in network with whom respondent has pooled money
0 51 (30.5) 56 (28.3) 1.0
1 42 (25.2) 54 (27.3) 1.2 (0.7–2.0) 0.576
2–3 43 (25.8) 55 (27.8) 1.2 (0.7–2.0) 0.587
4–5 31 (18.6) 33 (16.7) 1.0 (0.5–1.8) 0.922
Number of IDU in network who have used a syringe before the respondent used it
0 133 (79.6) 146 (73.7) 1.0
1 27 (16.2) 32 (16.2) 1.1 (0.6–1.9) 0.790
2–5 7 (4.2) 20 (10.1) 2.6 (1.1–6.4) 0.036
Number of IDU in network who have used other drug paraphernalia before respondent has used it.
0 105 (62.9) 119 (60.1) 1.0
1 29 (17.4) 31 (16.7) 0.9 (0.5–1.7) 0.841
2–5 33 (19.8) 48 (24.2) 1.3 (0.8–2.1) 0.342
Number of IDU in network who have initiated respondent to injection drug use
0 110 (65.9) 157 (79.3) 1.0
1 48 (28.8) 35 (17.7) 0.5 (0.3–0.8) 0.008
2–5 9 (5.4) 6 (3.0) 0.5 (0.2–1.4) 0.160
Number of IDU in network who have shown respondent how to inject drugs
0 104 (62.3) 147 (74.2) 1.0
1 43 (25.8) 39 (19.7) 0.6 (0.4–1.1) 0.083
2–5 20 (12.0) 12 (6.1) 0.4 (0.2–0.9) 0.027
Number of IDU in network who have injected respondent with drugs
0 89 (53.3) 88 (44.4) 1.0
1 44 (26.4) 54 (27.3) 1.2 (0.8–2.0) 0.392
2–5 34 (20.4) 56 (28.3) 1.7 (1.0–2.8) 0.054
Number of IDU in network who have used talwin/ritalin
0 139 (83.2) 119 (60.1) 1.0
1–3 17 (10.1) 42 (21.1) 2.9 (1.6–5.3) <0.001
4–5 11 (6.6) 37 (18.7) 3.9 (1.9–8.0) <0.001
Number of IDU in network who have used cocaine
0 113 (67.7) 120 (60.6) 1.0
1 23 (13.8) 36 (18.2) 1.5 (0.8–2.6) 0.192
2–3 17 (10.2) 30 (15.2) 1.7 (0.9–3.2) 0.125
4–5 14 (8.4) 12 (6.1) 0.8 (0.4–1.8) 0.605
Number of IDU in network who have used morphine
0 129 (77.3) 149 (75.3) 1.0
1 22 (13.2) 31 (15.7) 1.2 (0.7–2.2) 0.513
2–5 16 (9.6) 18 (9.1) 1.0 (0.5–2.0) 0.942
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Table 2: Odds ratios and 95% confidence intervals for univariate analysis of HBV serostatus.
Variable name HBV negative (n = 253) (%) HBV positive (n = 111) (%) OR (95% CI) p value
Respondent variables
Years of injection drug use (quartiles)
0–6 97 (38.3) 5 (4.5) 1.0
7–13 74 (29.3) 23 (20.7) 6.0 (2.2–16.6) <0.001
14–21 42 (16.6) 36 (32.4) 16.6 (6.1–45.3) <0.001
22–39 40 (15.8) 47 (42.3) 22.8 (8.4–61.5) <0.001
Gender
Male 150 (59.3) 60 (54.0) 1.0
Female 103 (40.7) 51 (46.0) 1.2 (0.8–1.9) 0.353
Education level
< grade 12 178 (70.4) 79 (71.2) 1.0
> grade 12 75 (29.6) 32 (28.8) 1.0 (0.6–1.3) 0.485
Ethnicity
Caucasian 99 (39.1) 29 (26.1) 1.0
Aboriginal 154 (60.9) 82 (73.9) 1.8 (1.1–3.0) 0.015
Mobility
In Winnipeg > 1 year 168 (66.4) 97 (87.4) 1.0
Moved to Winnipeg in past year 85 (33.6) 14 (12.6) 0.3 (0.2–0.5) <0.001
Deals drugs
No 129 (51.0) 61 (55.0) 1.0
Yes 124 (49.01 50 (45.1) 0.9 (0.5–1.3) 0.485
Cocaine use
No 85 (33.6) 44 (39.6) 1.0
Yes 168 (66.4) 67 (60.4) 0.8 (0.5–1.2) 0.27
Talwin/ritalin use
No 190 (75.1) 55 (49.6) 1.0
Yes 63 (24.9) 56 (50.5) 3.1 (1.9–4.9) <0.001
Morphine use
No 165 (64.8) 68 (61.3) 1.0
Yes 89 (35.2) 43 (38.7) 1.2 (0.7–1.8) 0.516
Heroin use
No 222 (87.8) 106 (95.5) 1.0
Yes 31 (12.3) 5 (4.5) 0.3 (0.1–0.9) 0.015
Injects daily
No 34 (13.4) 26 (23.4) 1.0
Yes 219 (86.6) 85 (76.6) 0.5 (0.3–0.9) 0.021
Injected at a hotel
No 160 (63.2) 53 (47.8) 1.0
Yes 93 (36.8) 58 (52.2) 1.9 (1.2–3.0) 0.006
injected at a shooting gallery
No 224 (88.5) 85 (62.2) 1.0
Yes 29 (11.5) 26 (23.4) 2.4 (1.3–4.2) 0.004
Ever used someone else's syringe
No 114 (45.1) 25 (22.5) 1.0
Yes 139 (54.9) 86 (77.5) 2.8 (1.7–4.7) <0.001
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No 204 (80.6) 66 (59.5) 1.0
Yes 49 (19.4) 45 (40.6) 2.8 (1.7–4.6) <0.001
Obtains syringes from friends
No 81 (32.0) 41 (16.9) 1.0
Yes 172 (68.0) 70 (63.1) 0.8 (0.5–1.3) 0.362
Obtains syringes from questionable sources
No 197 (77.9) 81 (73.0) 1.0
Yes 56 (22.1) 30 (27.0) 1.3 (0.8–2.2) 0.316
Opposite-sex regular partners
No 81 (32.0) 36 (32.4) 1.0
Yes 172 (68.0) 75 (67.6) 1.0 (0.6–1.6) 0.938
Opposite-sex casual partners
No 149 (58.9) 80 (72.1) 1.0
Yes 104 (41.1) 31 (27.9) 0.6 (0.3–0.9) 0.015
Opposite-sex client partners
No 223 (88.1) 90 (81.1) 1.0
Yes 30 (11.9) 21 (18.9) 1.7 (0.9–3.2) 0.081
Regular same-sex partners
No 245 (96.8) 109 (98.2) 1.0
Yes 8 (3.2) 2 (1.8) 0.6 (0.1–2.7) 0.448
Casual same-sex partners
No 240 (94.9) 109 (98.2) 1.0
Yes 13 (5.1) 2 (1.8) 0.3 (0.1–1.5) 0.113
Client same-sex partners
No 247 (97.6) 109 (98.2) 1.0
Yes 6 (2.4) 2 (1.8) 0.8 (0.2–3.8) 0.728
Egocentric network variables (maximum number of network members = 20)
Total number of IDU in network
Median (IQR) 3 (1,4) 3 (2,5) 1.1 (1.0–1.2) 0.001
Total number of IDU family members in network
Median (IQR) 0 (0,1) 0 (0,1) 1.3 (1.0–1.5) 0.019
Spouse IDU in network
No 169 (66.8) 69 (62.2) 1.0
Yes 84 (33.2) 42 (37.8) 1.2 (0.8–1.9) 0.394
IDU risk network variables (maximum number of IDU = 5)
Number of IDU respondent sees daily
None 83 (32.8) 38 (34.2) 1.0
1 84 (33.2) 38 (34.2) 1.0 (0.6–1.7) 0.965
2 48 (19.0) 13 (11.7) 0.6 (0.3–1.2) 0.155
3–5 38 (15.0) 22 (19.8) 1.3 (0.7–2.4) 0.479
Number of IDU in network who inject daily
None 160 (63.2) 50 (45.1) 1.0
1 42 (16.6) 25 (22.5) 1.9 (1.1–3.4) 0.032
2 31 (12.3) 17 (15.3) 1.8 (0.9–3.4) 0.101
3–5 20 (7.9) 19 (17.1) 3.0 (1.5–6.1) 0.002
Number of IDU in network who have been IDU for >5 years
0 142 (56.1) 34 (30.6) 1.0
1 50 (19.8) 18 (16.2) 1.5 (0.8–2.9) 0.223
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2 32 (12.7) 24 (21.6) 3.1 (1.6–6.0) 0.001
3–5 29 (11.5) 35 (31.5) 5.0 (2.7–9.4) <0.001
Number of IDU in network who have injected at a hotel
0 175 (69.2) 54 (48.7) 1.0
1 48 (19.0) 20 (18.0) 1.4 (0.7–2.5) 0.330
2–5 30 (11.9) 37 (33.3) 4.0 (2.3–7.1) <0.001
Number of IDU in network who have injected at a shooting gallery
0 204 (80.6) 74 (66.7) 1.0
1 30 (11.9) 15 (13.5) 1.4 (0.7–2.7) 0.351
2–5 19 (7.5) 22 (19.8) 3.2 (1.6–6.2) 0.001
Number of IDU in network with whom respondent has pooled money
0 84 (33.2) 23 (20.7) 1.0
1 62 (24.5) 33 (29.7) 1.9 (1.0–3.6) 0.037
2–3 64 (25.3) 34 (30.6) 1.9 (1.0–3.6) 0.036
4–5 43 (17.0) 21 (18.9) 1.8 (0.9–3.6) 0.103
Number of IDU in network who have used a syringe before the respondent used it
0 191 (75.5) 87 (78.4) 1.0
1 47 (18.6) 12 (10.8) 0.6 (0.3–1.1) 0.097
2–5 15 (5.9) 12 (10.8) 1.8 (0.8–3.9) 0.168
Number of IDU in network who have used other drug paraphernalia before respondent has used it.
0 155 (61.3) 67 (60.4) 1.0
1 46 (18.2) 13 (11.8) 0.7 (0.3–1.3) 0.220
2–5 52 (20.6) 31 (27.9) 1.4 (0.8–2.3) 0.234
Number of IDU in network who have initiated respondent to injection drug use
0 177 (70.0) 88 (79.2) 1.0
1 63 (24.9) 21 (18.9) 0.7 (0.4–1.2) 0.159
2–5 13 (5.1) 2 (1.8) 0.3 (0.1–1.4) 0.128
Number of IDU in network who have shown respondent how to inject drugs
0 172 (68.0) 79 (71.2) 1.0
1 58 (22.9) 23 (20.7) 0.9 (0.5–1.5) 0.602
2–5 23 (9.1) 9 (8.1) 0.8 (0.4–1.9) 0.700
Number of IDU in network who have injected respondent with drugs
0 133 (52.6) 43 (38.7) 1.0
1 65 (25.7) 33 (29.7) 1.6 (0.9–2.7) 0.103
2–5 55 (21.7) 35 (31.5) 2.0 (1.1–3.4) 0.015
Number of IDU in network who have used talwin/ritalin
0 197 (77.9 59 (53.2) 1.0
1–3 31 (12.3) 29 (26.1) 3.1 (1.7–5.6) <0.001
4–5 25 (9.9) 48 (13.2) 3.1 (1.6–5.8) 0.001
Number of IDU in network who have used cocaine
0 168 (66.4) 64 (57.7) 1.0
1 39 (15.4) 20 (18.0) 1.3 (0.7–2.5) 0.340
2–3 26 (10.3) 21 (18.9) 2.1 (1.1–4.0) 0.022
4–5 20 (7.9) 26 (7.1) 0.8 (0.3–2.0) 0.625
Number of IDU in network who have used morphine
0 198 (78.3) 80 (72.1) 1.0
1 34 (13.4) 18 (16.2) 1.3 (0.7–2.5) 0.399
2–5 21 (8.3) 13 (11.7) 1.5 (0.7–3.2) 0.258
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Table 3: Odds ratios and 95% confidence intervals for univariate analysis of HIV serostatus.
Variable name HIV negative (n = 334) (%) HIV positive (n = 26) (%) OR (95% CI) p value
Respondent variables
Years of injection drug use (quartiles)
0–6 100 (29.9) 2 (7.7) 1.0
7–13 83 (24.9) 11 (42.3) 6.6 (1.4–30.7) 0.016
14–21 71 (21.3) 7 (26.9) 4.9 (0.9–24.4) 0.051
22–39 80 (24.0) 6 (23.1) 3.75 (0.7–19.0) 0.111
Gender
Male 193 (57.8) 13 (50.0) 1.0
Female 141 (42.2) 13 (50.0) 1.4 (0.6–3.0) 0.442
Education level
< grade 12 234 (70.1) 19 (73.1) 1.0
> grade 12 100 (29.9) 7 (26.9) 0.9 (0.4–2.1) 0.744
Ethnicity
Caucasian 125 (37.4) 3 (11.5) 1.0
Aboriginal 209 (62.6) 23 (88.5) 4.6 (1.4–15.6) 0.004
Mobility
In Winnipeg > 1 year 244 (73.1) 18 (69.2) 1.0
Moved to Winnipeg in past year 90 (27.0) 8 (30.8) 1.2 (0.5–2.9) 0.677
Deals drugs
No 175 (52.4) 15 (57.7) 1.0
Yes 159 (47.6) 11 (42.3) 0.8 (0.4–1.8) 0.601
Cocaine use
No 122 (36.5) 6 (23.1) 1.0
Yes 212 (63.5) 20 (76.9) 1.9 (0.7–4.9) 0.154
Talwin/ritalin use
No 228 (68.3) 16 (61.5) 1.0
Yes 106 (31.7) 10 (38.5) 1.3 (0.6–3.1) 0.486
Morphine use
No 209 (62.6) 21 (80.8) 1.0
Yes 125 (37.4) 5 (19.2) 0.4 (0.1–1.1) 0.051
Heroin use
No 299 (89.5) 26 (100)
Yes 35 (10.5) 0 (0.00) Not defined
Injects daily
No 52 (15.6) 5 (19.2) 1.0
Yes 282 (84.4) 21 (80.8) 0.8 (0.3–2.1) 0.631
Injected at a hotel
No 198 (59.3) 16 (61.5) 1.0
Yes 136 (40.7) 10 (38.5) 0.9 (0.4–2.1) 0.821
injected at a shooting gallery
No 287 (85.9) 17 (65.4) 1.0
Yes 47 (14.1) 9 (34.6) 3.2 (1.4–7.7) 0.012
Ever used someone else's syringe
No 136 (40.7) 2 (7.7) 1.0
Yes 198 (59.3) 24 (92.3) 8.2 (1.9–35.5) <0.001
Injected someone else as a serviceBMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
Page 13 of 19
(page number not for citation purposes)
No 256 (76.7) 13 (50.0) 1.0
Yes 78 (23.3) 13 (50.0) 3.3 (1.5–7.4) 0.005
Obtains syringes from friends
No 106 (31.7) 13 (50.0) 1.0
Yes 228 (68.3) 13 (50.0) 0.5 (0.2–1.0) 0.063
Obtains syringes from questionable sources
No 257 (77.0) 19 (73.1) 1.0
Yes 77 (23.1) 7 (26.9) 1.2 (0.5–3.0) 0.658
Opposite-sex regular partners
No 105 (31.4) 8 (30.8) 1.0
Yes 229 (68.6) 18 (69.2) 1.0 (0.4–2.4) 0.944
Opposite-sex casual partners
No 208 (62.3) 18 (69.2) 1.0
Yes 126 (37.7) 8 (30.8) 0.7 (0.3–1.7) 0.474
Opposite-sex client partners
No 290 (86.8) 19 (73.1) 1.0
Yes 44 (37.7) 7 (26.9) 2.4 (1.0–6.1) 0.076
Regular same-sex partners
No 326 (97.6) 24 (92.3) 1.0
Yes 8 (2.4) 2 (7.7) 3.4 (0.7–16.9) 0.183
Casual same-sex partners
No 320 (95.8) 25 (96.2) 1.0
Yes 14 (4.2) 1 (3.9) 0.9 (0.1–7.2) 0.932
Client same-sex partners
No 329 (98.5) 23 (88.5) 1.0
Yes 5 (1.5) 3 (11.5) 8.6 (1.9–38.2) 0.013
Egocentric network variables (maximum number of network members = 20)
Total number of IDU in network
Median (IQR) 3 (2,5) 2 (0,5) 0.9 (0.8–1.1) 0.241
Total number of IDU family members in network
Median (IQR) 0 (0,1) 0 (0,2) 1.2 (0.9–1.6) 0.260
Spouse IDU in network
No 215 (64.4)) 17 (65.4) 1.0
Yes 119 (35.6) 9 (34.6) 1.0 (0.4–2.2) 0.917
IDU risk network variables (maximum number of IDU = 5)
Number of IDU respondent sees daily
None 107 (32.0) 12 (46.2) 1.0
1 112 (33.5) 6 (23.1) 0.5 (0.2–1.3) 0.154
2 58 (17.4) 5 (19.2) 0.8 (0.3–2.3) 0.637
3–5 57 (17.1) 3 (11.5) 0.5 (0.1–1.7) 0.256
Number of IDU in network who inject daily
None 191 (57.2) 17 (65.4) 1.0
1 63 (18.9) 2 (7.7) 0.4 (0.1–1.6) 0.176
2 45 (13.5) 4 (15.4) 1.0 (0.3–3.1) 0.998
3–5 35 (10.5) 3 (11.5) 1.0 (0.3–3.5) 0.954
Number of IDU in network who have been IDU for >5 years
0 159 (47.6) 14 (53.9) 1.0
1 65 (19.5) 3 (11.5) 0.5 (0.1–1.9) 0.323
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2 52 (15.6) 4 (15.4) 0.9 (0.3–2.8) 0.819
3–5 58 (17.4) 5 (19.2) 1.0 (0.3–2.8) 0.969
Number of IDU in network who have injected at a hotel
0 207 (62.0) 20 (76.9) 1.0
1 64 (19.2) 2 (7.7) 0.3 (0.1–1.4) 0.135
2–5 63 (18.9) 4 (15.4) 0.7 (0.2–2.0) 0.458
Number of IDU in network who have injected at a shooting gallery
0 254 (76.1) 20 (76.9) 1.0
1 43 (12.9) 2 (7.7) 0.6 (0.1–2.6) 0.488
2–5 37 (11.1) 4 (15.4) 1.4 (0.4–4.2) 0.582
Number of IDU in network with whom respondent has pooled money
0 94 (28.1) 12 (46.2) 1.0
1 91 (27.3) 4 (15.4) 0.3 (0.1–1.1) 0.074
2–3 90 (27.0) 6 (23.1) 0.5 (0.2–1.5) 0.213
4–5 59 (17.7) 4 (15.4) 0.5 (0.2–1.7) 0.292
Number of IDU in network who have used a syringe before the respondent used it
0 255 (76.4) 20 (76.9) 1.0
1 56 (16.8) 4 (15.4) 0.9 (0.3–2.8) 0.869
2–5 23 (6.9) 2 (7.7) 1.1 (0.2–5.0) 0.894
Number of IDU in network who have used other drug paraphernalia before respondent has used it.
0 201 (60.2) 17 (65.4) 1.0
1 59 (17.7) 3 (11.5) 0.6 (0.2–2.1) 0.429
2–5 74 (22.2) 6 (23.1) 1.0 (0.4–2.5) 0.932
Number of IDU in network who have initiated respondent to injection drug use
0 242 (72.5) 21 (80.8) 1.0
1 77 (23.1) 5 (19.2) 0.7 (0.3–2.1) 0.563
2–5 15 (4.5) 0 (0.0) Not defined
Number of IDU in network who have shown respondent how to inject drugs
0 229 (68.6) 19 (73.1) 1.0
1 75 (22.5) 6 (23.1) 1.0 (0.4–2.5) 0.940
2–5 30 (9.0) 1 (3.9) 0.4 (0.1–3.1) 0.382
Number of IDU in network who have injected respondent with drugs
0 161 (48.2) 12 (46.2) 1.0
1 95 (28.4) 5 (19.2) 0.7 (0.2–2.1) 0.525
2–5 78 (23.4) 9 (34.6) 1.5 (0.6–3.8) 0.344
Number of IDU in network who have used talwin/ritalin
0 239 (71.6) 17 (65.4) 1.0
1–3 54 (16.2) 4 (15.4) 1.0 (0.3–3.2) 0.944
4–5 41 (12.3) 5 (19.2) 1.7 (0.6–4.9) 0.315
Number of IDU in network who have used cocaine
0 210 (62.9) 18 (69.2) 1.0
1 55 (16.5) 3 (11.5) 0.6 (0.2–2.2) 0.481
2–3 44 (13.2) 4 (15.4) 1.1 (0.3–3.3) 0.919
4–5 25 (7.5) 1 (3.9) 0.5 (0.1–3.6) 0.467
Number of IDU in network who have used morphine
0 255 (76.4) 21 (80.8) 1.0
1 46 (13.8) 4 (15.4) 1.1 (0.3–3.2) 0.924
2–5 33 (9.9) 1 (3.9) 0.4 (0.0–2.8) 0.336
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After adjusting for these interactions, two respondent var-
iables, obtaining needles from friends and injecting some-
one as a service, were no longer significant.
HBV was positively associated with three respondent var-
iables: years of ID use, injection with a used syringe, and
injection at a shooting gallery and two IDU risk network
variables: the number of IDU in the risk network who
injected talwin/ritalin, and the number who had injected
at a hotel (table 6). The latter variable was significant only
if the respondent identified 2 or more IDU in the risk net-
work with this characteristic. HBV was negatively associ-
ated with reporting opposite-sex casual sex partners;
moving to Winnipeg in the past year and the number of
IDU in the risk network who had initiated the respondent
to injection drug use. As above, this variable was only sig-
nificant if 2 or more IDU in the risk network were
reported as having initiated the respondent to injection
drug use.
HIV was positively associated with four respondent varia-
bles; injection with used syringes, injection at a shooting
gallery, same-sex client sex partners and aboriginal ethnic-
ity (table 7).
Discussion
Our two primary goals in this investigation were to deter-
mine which respondent and/or network variables were
Table 5: Adjusted odds ratios and 95% CI for interactions between injection with a used syringe and the IDU risk network variables.
A)
Reported injection with used syringe
Yes No
Number of talwin/ritalin users in IDU risk network 0 7.9 (3.7–16.8)
95 HCV +/58 HCV - (62%)
1.00
24 HCV +/81 HCV - (22.9%)
1–3 0.6 (0.3–42.4)
26 HCV +/10 HCV - (72%)
1.00
16 HCV +/7 HCV - (69.6%)
4–5 1.0 (0.2–156.8)
28 HCV +/9 HCV - (76%)
1.00
9 HCV +/2 HCV - (81.8%)
B)
Reported injection with used syringe
Yes No
Number of IDU who have shown the respondent how to inject 
drugs
0 7.9 (3.7–16.8)
111 HCV +/41 HCV - 
(73.0%)
1.00
36 HCV +/63 HCV - (36.4%)
1 7.7 (0.3–37.1)
31 HCV +/23 HCV - (57.4%)
1.00
8 HCV +/20 HCV - (28.6%)
2–5 0.4 (0.2–87.2)
7 HCV +/13 HCV - (33.3%)
1.00
5 HCV +/7 HCV - (41.6%)
(A) number of IDU in the network who used talwin/ritalin or (B) have shown the respondent how to inject. Serostatus data for HCV corresponding 
to each cell is also shown.
Table 4: HCV multivariate adjusted OR and 95% CI.
Variable name OR (95% CI) p value
Years of injection drug use 
Categories based on quartiles (Q1–Q4 below)
Q2 vs. Q1 3.1 (1.5–6.2) 0.002
Q3 vs. Q1 10.8 (4.8–24.5) <0.001
Q4 vs. Q1 10.3 (4.7–22.6) <0.001
injected at a shooting gallery
Yes vs. no 4.3 (1.8–10.5) <0.001
Ever used someone else's used syringe See table 5
Number of IDU in network who use talwin/ritalin See table 5
Number of IDU in network who have shown respondent how to inject drugs See table 5BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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associated with HCV, HBV, and HIV in our setting and to
compare and contrast these variables for the different
pathogens. Only two respondent variables were positively
associated with all three pathogens: injection with
syringes previously used by another IDU and injection at
a shooting gallery. The former represents a direct route for
parenteral transmission of blood borne pathogens and is
clearly a common factor for transmission of all three of
the pathogens examined in our study area. The latter,
given the high-risk activities characteristic of this type of
venue [6,18,19], would be associated with an increased
likelihood of exposure through purposeful or accidental
use of contaminated equipment. Although this variable is
a marker for high-risk behaviour on the part of individu-
als, it is also a proxy marker for membership in high risk,
largely anonymous networks of IDU. Networks form
around specific places where geographic place is the com-
mon connecting tie between individuals [22-24]. Includ-
ing place in network analysis adds explanatory power for
understanding disease transmission regardless of the
infection. Here shooting galleries are not simply high risk
environments for individual users, but, by acting as repos-
itories for contaminated equipment, they create bridging
opportunities for pathogens between individuals who
may not know each other and who may never otherwise
meet.
Like shooting galleries, certain hotels in Winnipeg are also
important venues for injection and favor formation of
place-based networks of IDU. The likelihood of HBV
infection increased proportional to the number of IDU
the respondent knew who had injected at a hotel. Associ-
ation with HBV, but not with HCV or HIV, could result
from HBV entering the hotel network(s) earlier than HCV
and HIV, resulting in more extensive spread. Alternatively,
there may be specific behaviours associated with this
group of IDU that favour specific transmission of this
pathogen (e.g. hotel rooms, as opposed to shooting gal-
leries, may offer more privacy and a greater likelihood of
engaging in sexual activities, thus favouring HBV trans-
mission over HCV). Regardless of the causal factors
involved, like others [8,25], we found that incorporating
interactions with risk network members provided a clearer
understanding of what actually constitutes high-risk
behaviour.
Respondents' injection of talwin/ritalin and their use by
IDU network members was a marker for HCV and HBV.
The type of drug used can loosely demarcate distinct net-
works of IDU [15,16]. Within these networks specific
Table 7: HIV multivariate adjusted OR
Variable name OR (95% CI) p value
Ethnicity
Aboriginal vs. caucasian 4.4 (1.2–15.6) 0.022
Ever used someone else's used syringe
Yes vs. No 8.7 (2.0–38.5) 0.004
injected at a shooting gallery
Yes vs. no 3.0 (1.2–7.5) 0.018
Same-sex client sex partners
Yes vs No 6.9 (1.5–32.4) 0.014
Table 6: HBV multivariate adjusted OR
Variable name OR (95% CI) p value
Years of injection drug use 
Categories based on quartiles (Q1–Q4 below)
Q2 vs. Q1 4.7 (1.6–13.9) 0.005
Q3 vs. Q1 11.3 (3.8–33.2) <0.001
Q4 vs. Q1 15.7 (5.3–46.5) <0.001
Ever used someone else's used syringe
Yes vs. No 2.2 (1.2–4.0) 0.005
injected at a shooting gallery
Yes vs. no 2.9 (1.3–6.3) 0.020
Opposite-sex casual sex partners
Yes vs No 0.5 (0.3–0.9) 0.020
Mobility (Moved to Winnipeg in past year)
Yes vs. no 0.3 (0.2–0.7) 0.004
Number of IDU in network who use talwin/ritalin
1–3 vs. none 2.9 (1.4–5.9) <0.005
4–5 vs none 3.2 (1.4–7.2) <0.009
Number of IDU in network who have intiated respondent to injection drug use
1 vs. none 0.6 (0.3–1.4) 0.248
2–5 vs. none 0.1 (0.02–0.8) 0.023
Number of IDU in risk network who have injected at a hotel
1 vs. none 1.3 (0.6–2.6) 0.490
2–5 vs. none 2.8 (1.3–5.9) 0.006BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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behaviours may favour transmission (e.g. the room tem-
perature production of cocaine vs. the need to heat some
other types of drugs [14]). To our knowledge, extensive
use of talwin/ritalin is relatively rare outside of the Cana-
dian provinces of Manitoba and Saskatchewan. It is nota-
ble that in our analysis, injection with used syringes
interacted with talwin/ritalin such that the prevalence of
HCV was high amongst talwin/ritalin users regardless of
whether or not they reported injection with used syringes.
Like cocaine, talwin/ritalin is typically prepared at room
temperature and frequently involves communal use of the
prepared drug and filters, which may account for the high
prevalence of HCV regardless of syringe sharing practices
(typically pills are crushed in room temperature water;
IDU then use a common filter to draw drug into their own
respective syringes). It is also notable, that HIV does not
show a positive association with talwin/ritalin in contrast
to HCV and HBV. As above, this may reflect a different
temporal framework for pathogen entry to the network of
talwin/ritalin users. If this is the case, the same behaviours
which facilitated spread of HBV and HCV may ultimately
lead to high HIV prevalence in this group.
Two IDU risk network variables were negatively associ-
ated with either HCV or HBV. For HBV, there was a nega-
tive association with the number of IDU in the
respondent's risk network who had initiated them to
injection drug use, while for HCV there was a negative
association if the respondent reported that there were IDU
in their risk network who had shown them how to inject
drugs. For HCV, there was also a weak interaction between
the number of IDU members who had shown the
respondent how to shoot drugs and syringe sharing, such
that syringe sharing was no longer positively associated
with prevalence. In general, these network variables may
mark small, relatively closed networks of IDU who may
share equipment and syringes, but rarely admit new mem-
bers. Low network turnover has been associated with
lower risk [12] as opportunities for entry of pathogens to
these networks (via infected individuals) would be corre-
spondingly reduced. An area worthy of research would be
whether the lower prevalence of infection is a chance
byproduct of the social interactions within these networks
or whether the individuals within closed networks are
actively and knowingly attempting to isolate themselves
from infection risk.
The greater likelihood of HIV and HBV being transmitted
through sexual contact was consistent with sex partner-
related variables being retained in the final models for
these two pathogens. However, while a positive correla-
tion for HIV occurred with same-sex client partners, the
directionality for HBV and opposite-sex casual partners
was opposite. Although the direction of this relationship
appears counter-intuitive, it may reflect a greater likeli-
hood to engage in safer sex harm reduction activities with
sex partners of this type. This question could be addressed
in more detailed research on sexual contact behaviours in
this population.
Aboriginal ethnicity and a recent move to Winnipeg were
associated with HIV and HBV, respectively. HIV was the
only pathogen where ethnicity remained as an independ-
ent predictor of risk in the final model. Research in other
cities have identified specific social network interactions
that can account for ethnic differences in disease preva-
lence [13]. Further research would be necessary within our
study population to identify what risk behaviour(s) may
be associated with HIV infection in the aboriginal popula-
tion in Manitoba that may not have been captured by our
survey. The relatively small number of HIV positive indi-
viduals in our dataset also may have limited the analytic
potential for this pathogen in regression analysis. A recent
move to Winnipeg was associated with a lesser likelihood
of HBV positivity. This pattern may reflect a lower preva-
lence of HBV and/or earlier or more extensive deployment
of vaccination programs in the provinces from which
these IDU originated (e.g. the province of British Colum-
bia began vaccinating approximately 6 years prior to
Manitoba).
A number of limitations for the study should be noted.
First, the study was cross-sectional and hence does not
provide any data on trends or whether currently observed
behaviours were a result of, rather than the cause of, an
infection by one of the pathogens studied. Second, the
data were egocentric and hence no independent valida-
tion of the behaviours of IDU in the risk network was pos-
sible. Third, network members were elicited based on
contact in the previous 30 days, but questions regarding
individual behaviours and interactions with network
members were typically collected for the previous 6
months (or longer periods for some variables such as
"ever-use of someone else's syringe"). Time frames are rel-
evant, given the noted lack of correlation between some
known risk behaviours and serostatus in our analysis (see
paragraph below). Any comparisons of our results with
those from other areas would need to take note of the
time frames used. Fourth, the egocentric and IDU risk net-
works were truncated at 20 and 5 people, respectively. The
implications of this data truncation are greatest for the
IDU risk network variables as they formed a large part of
the analysis. Overall, 17% of respondents reported more
than 5 IDU in their egocentric network. We felt that full
data collection on all IDU in the egocentric network was
impractical in terms of time, complexity of data collection
and accurate recall by respondents, however, it should be
noted that this additional data could have revealed addi-
tional patterns not apparent in our results.BMC Public Health 2006, 6:229 http://www.biomedcentral.com/1471-2458/6/229
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Finally, some limitations regarding specific variables
should be noted. First, data on sharing of drug-prepara-
tion equipment and transfer of prepared drugs between
syringes was available for only the six months prior to
interview. In contrast, sharing of used syringes was based
both on six-month and "ever" data. Only the latter was a
predictor of risk, therefore, if more extensive data had
been collected for equipment sharing and drug transfers,
they may also have been significant predictors of risk of
infection for some, or all, of the pathogens studied. Sec-
ond, only a limited number of sexual behaviour questions
were included in the study and no specific questions on
type of sex were asked. Collection of data on anal sex, in
particular, could have revealed other correlations not evi-
dent with the dataset available. Third, only "injecting
someone else as a service" was analyzed; "injecting some-
one else as a favor" or "receiving injections from others"
can be considered distinct traits and could also be related
to the common use of syringes and pathogen transmis-
sion.
Conclusion
Our findings reinforce the clear link between respondent
behaviours (e.g. injection with someone else's used
syringe) and risk of infection. However, they also high-
light the importance of defining the types of personal net-
works that form within an area and identifying the
different patterns of transmission of pathogens within
those networks. In our setting, pathogen transmission is
associated with loosely defined, sometimes anonymous,
high-risk networks formed around specific venues (shoot-
ing galleries, hotels) or between users who are linked by
their drug use preferences. Smaller, somewhat isolated
pockets of IDUs appear to exist within the larger popula-
tion where behavioural patterns pose a lesser risk, unless,
or until, a given pathogen enters those networks. Tempo-
ral differences with respect to pathogen introduction to
the different networks likely influences which specific
behaviours appear as protective or as high-risk, highlight-
ing the importance of verifying the extent to which risk
behaviours or markers identified as important in one set-
ting or to one pathogen apply to other settings or patho-
gens. The lack of any apparent correlation between the
prevalent infections for the three pathogens, noted in the
results section, reinforces the need to identify the different
social and temporal patterns associated with the various
pathogens that may be circulating within a population.
Both individual- and network-level concepts assist in
characterizing and comparing the transmission of HCV
and HBV, as well as, HIV.
A potential hierarchy of risk emerges, defined by space
and time. Individuals may have some independence in
their decisions to use drugs or not, or share syringes or
not. However, the broader personal network in which
they find themselves, whether defined by living near a
hotel where drug use is common or by their ethnic or age
group, is no less important in contributing to their poten-
tial for initiation of specific behaviours or exposure to
infectious agents. The smaller, more specific social inter-
actions with their IDU risk network forms an additional
step in a progression which may determine an individ-
ual's choice of drug; their norms, rituals and/or practices
of injection; and their likelihood of exposure to infected
individuals. Both individual- and network-level concepts
assist in characterizing and comparing the transmission of
HCV, HBV, and HIV and determining the underlying pat-
terns that drive the social connections between individu-
als that may favour or hinder transmission of specific
pathogens.
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